S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
NASDAQ:BPMC

Blueprint Medicines - BPMC Stock Forecast, Price & News

$46.74
+0.03 (+0.06%)
(As of 01/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$46.28
$47.68
50-Day Range
$41.92
$50.19
52-Week Range
$40.78
$85.67
Volume
385,905 shs
Average Volume
451,390 shs
Market Capitalization
$2.80 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$78.11

Blueprint Medicines MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
67.1% Upside
$78.11 Price Target
Short Interest
Bearish
8.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.55mentions of Blueprint Medicines in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$1.03 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($9.38) to ($9.71) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

679th out of 1,055 stocks

Pharmaceutical Preparations Industry

347th out of 518 stocks


BPMC stock logo

About Blueprint Medicines (NASDAQ:BPMC) Stock

Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases, blood disorders, and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Receive BPMC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter.

BPMC Stock News Headlines

Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Blueprint Medicines (NASDAQ:BPMC) Price Target Cut to $44.00
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Barclays Keeps Their Hold Rating on Blueprint Medicines (BPMC)
BPMC.O - | Stock Price & Latest News | Reuters
See More Headlines
Receive BPMC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter.

BPMC Company Calendar

Last Earnings
10/27/2021
Today
1/31/2023
Next Earnings (Estimated)
2/15/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BPMC
Fax
N/A
Employees
495
Year Founded
2011

Price Target and Rating

Average Stock Price Forecast
$78.11
High Stock Price Forecast
$115.00
Low Stock Price Forecast
$41.00
Forecasted Upside/Downside
+67.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
16 Analysts

Profitability

Net Income
$-644,090,000.00
Net Margins
-263.54%
Pretax Margin
-261.03%

Debt

Sales & Book Value

Annual Sales
$180.08 million
Book Value
$16.50 per share

Miscellaneous

Free Float
57,785,000
Market Cap
$2.80 billion
Optionable
Optionable
Beta
0.64

Social Links


Key Executives

  • Kathryn Haviland
    President, Chief Executive Officer & Director
  • Christina RossiChristina Rossi
    Chief Operating Officer
  • Michael Landsittel
    Chief Financial Officer
  • Christopher K. Murray
    Senior Vice President-Technical Operations
  • Becker HewesBecker Hewes
    Chief Medical Officer













BPMC Stock - Frequently Asked Questions

Should I buy or sell Blueprint Medicines stock right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 1 sell rating, 6 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BPMC shares.
View BPMC analyst ratings
or view top-rated stocks.

What is Blueprint Medicines' stock price forecast for 2023?

16 Wall Street analysts have issued 12 month target prices for Blueprint Medicines' stock. Their BPMC share price forecasts range from $41.00 to $115.00. On average, they predict the company's stock price to reach $78.11 in the next twelve months. This suggests a possible upside of 67.1% from the stock's current price.
View analysts price targets for BPMC
or view top-rated stocks among Wall Street analysts.

How have BPMC shares performed in 2023?

Blueprint Medicines' stock was trading at $43.81 at the beginning of 2023. Since then, BPMC shares have increased by 6.7% and is now trading at $46.74.
View the best growth stocks for 2023 here
.

When is Blueprint Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 15th 2023.
View our BPMC earnings forecast
.

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Co. (NASDAQ:BPMC) announced its earnings results on Wednesday, October, 27th. The biotechnology company reported ($2.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.63) by $0.37. The biotechnology company had revenue of $24.19 million for the quarter, compared to the consensus estimate of $42.58 million. Blueprint Medicines had a negative trailing twelve-month return on equity of 56.45% and a negative net margin of 263.54%. Blueprint Medicines's revenue for the quarter was down 96.8% on a year-over-year basis. During the same quarter last year, the company earned $11.16 EPS.

What guidance has Blueprint Medicines issued on next quarter's earnings?

Blueprint Medicines issued an update on its FY 2022 earnings guidance on Thursday, January, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $200.00 million-$200.00 million, compared to the consensus revenue estimate of $199.69 million.

What is Kate Haviland's approval rating as Blueprint Medicines' CEO?

16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Glassdoor.com. Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend.

What other stocks do shareholders of Blueprint Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR).

When did Blueprint Medicines IPO?

(BPMC) raised $115 million in an IPO on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Blueprint Medicines' stock symbol?

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

Who are Blueprint Medicines' major shareholders?

Blueprint Medicines' stock is owned by a number of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (0.21%), Comerica Bank (0.13%), New York State Common Retirement Fund (0.09%), Assenagon Asset Management S.A. (0.06%), Moody Aldrich Partners LLC (0.03%) and Oak Ridge Investments LLC (0.03%). Insiders that own company stock include Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, Christina Rossi, Christopher K Murray, Debra Durso-Bumpus, Fouad Namouni, George Demetri, Jeffrey W Albers, Kate Haviland, L Becker Hewes, Marion Dorsch, Mark Alan Goldberg, Nicholas Lydon, Percy H Carter and Tracey L Mccain.
View institutional ownership trends
.

How do I buy shares of Blueprint Medicines?

Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Blueprint Medicines' stock price today?

One share of BPMC stock can currently be purchased for approximately $46.74.

How much money does Blueprint Medicines make?

Blueprint Medicines (NASDAQ:BPMC) has a market capitalization of $2.80 billion and generates $180.08 million in revenue each year. The biotechnology company earns $-644,090,000.00 in net income (profit) each year or ($12.10) on an earnings per share basis.

How many employees does Blueprint Medicines have?

The company employs 495 workers across the globe.

How can I contact Blueprint Medicines?

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.blueprintmedicines.com. The biotechnology company can be reached via phone at (617) 374-7580 or via email at ir@blueprintmedicines.com.

This page (NASDAQ:BPMC) was last updated on 2/1/2023 by MarketBeat.com Staff